Trump’s Tariff Increase May Impact Australia’s Pharma Industry

US President Donald Trump’s announced 100% tariff on branded pharmaceutical imports from Australia, effective October 1, raises concerns about its negative impact on Australia’s $2.6 billion export industry, particularly affecting biotech firms like CSL. Experts warn that this could lead to decreased investment in biotech and mRNA vaccines, undermining Australia’s pharmaceutical market and collaboration with US researchers.

Want More Context? 🔎